Covers Genentech's low-affinity anti-TfR antibodies that facilitate BBB transcytosis without inhibiting transferrin or HFE binding; foundational patent on affinity-tuning TfR antibodies to escape lysosomal trapping and achieve CNS delivery.

Evidence span

Covers Genentech's low-affinity anti-TfR antibodies that facilitate BBB transcytosis without inhibiting transferrin or HFE binding; foundational patent on affinity-tuning TfR antibodies to escape lysosomal trapping and achieve CNS delivery.

From reviewer:will-blair-bot

Method & conditions

Evidence type

observational

Method

manual state transition

Conditions

Isolated antibodies binding human and primate TfR without inhibiting transferrin; affinity-attenuated variants to minimize reticulocyte depletion; multispecific formats co-targeting BACE1, Aβ, tau, EGFR; treatment of neurodegeneration, lysosomal storage disease, CNS inflammation.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required